Morrow Sodali will act as Information Agent in the Pfizer - Medivation M&A deal.
The Companies have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
Related News
Sodali & Co Shortlisted for Multiple Transform Awards ANZ 2025
01 October 2025
Sodali & Co Celebrates Excellence in Financial PR
31 August 2025
How to Prep a CEO For the Scrutiny of Life Post-IPO: ECM Watch
25 August 2025
Sodali & Co Appoints Emily Wei and Hasib Nasirullah as Co-Leads of Global Sustainability Practice
19 August 2025
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right